18 18. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem‐cell transplantation. Blood. 2007; 110(9):3463–3471.
19 19. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355(15):1572–1582.
20 20. Chow EJ, Anderson L, Baker KS, et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant. 2016; 22(5):782–795.
21 21. Eshelman‐Kent D, Kinahan KE, Hobbie W, et al. Cancer survivorship practices, services, and delivery: a report from the Children's Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees. J Cancer Surviv. 2011; 5(4):345–357.
22 22. Cupit MC, Duncan C, Savani BN, Hashmi SK. Childhood to adult transition and long‐term follow‐up after blood and marrow transplantation. Bone Marrow Transplant. 2016; 51(2):176–181.
23 23. Kadan‐Lottick NS, Robison LL, Gurney JG, et al. Childhood cancer survivors' knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002; 287(14):1832–1839.
24 24. Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long‐term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008; 26(27):4401–4409.
25 25. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004; 2(1):61–70.
26 26. Henderson TO, Friedman DL, Meadows AT. Childhood cancer survivors: transition to adult‐focused risk‐based care. Pediatrics. 2010; 126(1):129–136.
27 27. Denzen EM, Thao V, Hahn T, et al. Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study. Bone Marrow Transplant. 2016; 51(9):1233–1240.
28 28. Campbell MK, Tessaro I, Gellin M, et al. Adult cancer survivorship care: experiences from the LIVESTRONG centers of excellence network. J Cancer Surviv. 2011; 5(3):271–282.
29 29. Bhatia S, Meadows AT. Long‐term follow‐up of childhood cancer survivors: future directions for clinical care and research. Pediatr Blood Cancer. 2006; 46(2):143–148.
30 30. Grant M, Economou D, Ferrell B, Uman G. Educating health care professionals to provide institutional changes in cancer survivorship care. J Cancer Educ. 2012; 27(2):226–232.
31 31. McCabe MS, Baker SK, Huffman C, Miller K. Optimizing Survivorship Care: Academic and Community Clinical Models. In: Feuerstein M, Ganz PA (eds). Health Services for Cancer Survivors. New York, NY: Springer, 2011; pp. 223–238.
32 32. Friedman DL, Freyer DR, Levitt GA. Models of care for survivors of childhood cancer. Pediatr Blood Cancer. 2006; 46(2):159–168.
33 33. Children’s Oncology Group Nursing Discipline, Clinical Practice Subcommittee/Survivorship, Late Effects Committee. Establishing and Enhancing Services for Childhood Cancer Survivors: Long‐Term Follow‐Up Program Resource Guide. 2007. Available from: http://www.survivorshipguidelines.org/pdf/LTFUResourceGuide.pdf (accessed 10 September 2020).
34 34. Kurosawa S, Mori A, Tsukagoshi M, et al. Current status and needs of long‐term follow‐up clinics for hematopoietic cell transplant survivors: results of a nationwide survey in Japan. Biol Blood Marrow Transplant. 2020; 26(5):949–955.
35 35. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(3):337–341.
36 36. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006; 37(3):249–261.
37 37. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006; 12(2):138–151.
38 38. National Marrow Donor Program Be the Match. 2019 Long‐term survival guidelines: post‐transplant care recommendations. 2019. Available from: https://bethematchclinical.org/workarea/downloadasset.aspx?id=17174 (accessed 10 September 2020).
39 39. Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016; 51(6):778–785.
40 40. Passweg JR, Baldomero H, Basak GW, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non‐HCT cell therapies. Bone Marrow Transplant. 2019; 54(10):1575–1585.
41 41. Chandy M. Stem cell transplantation in India. Bone Marrow Transplant. 2008; 42(Suppl 1):S81–S84.
42 42. Iida M, Kodera Y, Dodds A, et al. Advances in hematopoietic stem cell transplantation in the Asia‐Pacific region: the second report from APBMT 2005‐2015. Bone Marrow Transplant. 2019; 54(12):1973–1986.
43 43. Naithani R. Hematopoietic Stem Cell Transplantation in India‐2017 Annual Update. Indian J Hematol Blood Transfus. 2018; 34(1):5–7.
44 44. World Health Organization. Road traffic injuries. 2020. Available from: https://www.who.int/news‐room/fact‐sheets/detail/road‐traffic‐injuries (accessed 14 April 2020).
CHAPTER 4 Telemedicine in patient care of long‐term transplant survivors
Catherine J. Lee1, Mihkaila Wickline2, and Mary E.D. Flowers3
1 Utah Blood and Marrow Transplant Program, Huntsman Cancer Institute, Salt Lake City, UT, USA
2 Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3 Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, Seattle, WA, USA
Introduction
Telemedicine is a quickly expanding mode of healthcare and is garnering great interest for its potential to improve access in a cost‐efficient manner to long‐term Hematopoietic Cell Transplant (HCT) survivorship care. Telemedicine, broadly defined as delivery of medicine from a distance, encompasses a range of technology spanning from the internet, telephones or smartphones, or other mobile wireless devices to provide a range of healthcare services and exchange of information [1].
One of the earliest reported uses for telemedicine was for acute conditions, such as ischemic stroke, as this life‐threatening condition required critical and time‐sensitive determination of fibrinolytic therapy from a remote neurologist [2]. Telemedicine has also been used to deliver care for those in the military, prisons, and rural locations and, more recently, it has been utilized for chronic medical conditions [3,4]. In the past few years, telemedicine has had an increasing presence in the delivery of oncology care. Beginning in the late 1990s, Doolittle and colleagues from the University of Kansas Medical Center